OPKO Health reports Q3 2026 results and BioReference sale agreement
FROM THE WIRE · GLOBENEWSWIRE.COM
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results for the third quarter ended September 30, 2026. Third Quarter 2026 and Recent Business Highlights OPKO…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralQuarterly results plus a divestiture agreement, relevant for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01OPKO Health published its third quarter 2026 results.
- 02The company agreed with Labcorp to sell substantially all remaining BioReference diagnostic operations.
- 03The release highlights recent business developments.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets